Recursion, artificial intelligence drug design specialists, have signed a lucrative deal to collaborate with Roche and Genetech to identify drug targets for neurological disorders and cancer. The deal, which begins with a $150 million payment, spans up to 40 different projects. With milestone payments and royalties, each individual project could net Recursion over $300 million.
According to Conor Hale of Fierce Biotech, “That means that on the remote possibility that Recursion’s AI bats 1,000, and every drug makes it through clinical trials all the way to market, the company could reap more than $12 billion. In the company’s words, the agreement could prove transformational.”
Read more about the deal by clicking here.
(Source: Fierce Biotech, December 7th, 2021)